Jeffrey Humphrey Net Worth

Jeffrey Humphrey biography

Dr. Jeffrey Humphrey serves as Chief Medical Officer of the Company. He has been appointed as Chief Medical Officer of the Company effective 6/22/2020. He served in various positions at affiliates of Kyowa Kirin Co. Ltd., or Kyowa Kirin, a pharmaceutical company, from April 2012 to June 2020. At Kyowa Kirin, he served as chief development officer from August 2019 to June 2020, as president and chief medical officer of Kyowa Kirin Pharmaceutical Development, Inc. from April 2013 to August 2019, and as senior vice president, drug development of Kyowa Hakko Kirin Pharma, Inc. from April 2012 to March 2013. He previously served in senior management positions for early and late drug development and medical affairs at Pfizer, Bayer, and Bristol Myers Squibb. Dr. Humphrey holds a A.B. from Harvard University and an M.D. from Case Western Reserve University School of Medicine.

How old is Jeffrey Humphrey?

Jeffrey Humphrey is 59, he's been the Chief Medical Officer of Constellation Pharmaceuticals Inc since 2020. There are 2 older and 6 younger executives at Constellation Pharmaceuticals Inc. The oldest executive at Constellation Pharmaceuticals Inc is James Audia, 64, who is the Director.

What's Jeffrey Humphrey's mailing address?

Jeffrey's mailing address filed with the SEC is C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON ROAD, SOUTH BLDG, BEDFORD, MA, 01730.

Insiders trading at Constellation Pharmaceuticals Inc

Over the last 15 years, insiders at Constellation Pharmaceuticals Inc have traded over $36,293,867 worth of Constellation Pharmaceuticals Inc stock and bought 6,651,976 units worth $88,473,679 . The most active insiders traders include Peter Svennilson, Of The University Of Califo... és Anthony B Evnin. On average, Constellation Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $4,934,940. The most recent stock trade was executed by Mark A Goldsmith on 4 March 2021, trading 14,987 units of CNST stock currently worth $509,408.

What does Constellation Pharmaceuticals Inc do?

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel therapeutics that selectively modulate gene expression to address serious unmet medical needs in patients with cancer. The Company has a deep understanding of how epigenetic and chromatin modifications in cancer cells and in the tumor and immune microenvironment play a fundamental role in driving disease progression and drug resistance. Constellation is driving development of the BET inhibitor CPI-0610 for the treatment of myelofibrosis as well as the EZH2 inhibitor CPI-0209 for the treatment of solid tumors. The Company is also applying its broad research and development capabilities to explore other novel targets that directly and indirectly impact gene expression to fuel a sustainable pipeline of innovative small-molecule product candidates.

Constellation Pharmaceuticals Inc executives and stock owners

Constellation Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jigar Raythatha,
  President, Chief Executive Officer, Director
• Emma Reeve,
  Chief Financial Officer, Senior Vice President, Treasurer
• Scott Braunstein,
  Independent Director
• Mark Goldsmith,
  Independent Chairman of the Board
• Robert Tepper,
  Independent Director
• James Audia,
  Director
• Elizabeth Trehu,
  Independent Director
• Steven Hoerter,
  Independent Director
• Ronald Aldridge,
  IR Contact Officer
• Richard Levy,
  Independent Director
• Jeffrey Humphrey,
  Chief Medical Officer
• Karen Valentine,
  Chief Legal Officer, General Counsel
• Patrick Trojer,
  Chief Scientific Officer
• Group L Pcolumn Group Gp, L...,
  
• Group L Pcolumn Group Iii, ...,
  
• Group L Pgoeddel David V Sv...,
  
• Group L Pcolumn Group Iii, ...,
  
• Rock Ventures Lp Third Rock...,
  
• Advisors Llc Orbi Med Globa...,
  
• Of The University Of Califo...,
  
• Capital, Llc Casdin Partner...,
  
• Peter Svennilson,
  Director
• Ventures Ii, Lp Spur Capita...,
  
• Fund L.P.Topspin Biotech Fu...,
  
• Berg Ltd Mountain,
  10% owner
• Anthony B Evnin,
  Director
• Group L Pcolumn Group Gp, L...,
  
• Onco Ltd Precision,
  10% owner
• Venture Investments, Llc Al...,
  10% owner
• James E Deerfield Mgmt L.P....,
  
• Jerry A Hatfield,
  Sr. Vice President, Operations
• Michael John Hoffman,
  President and CEO
• Daniel Ingram,
  Senior V.P., Sales/Marketing
• James Ct Bolton,
  Senior Vice President
• James A Lewis,
  Director
• Frank J Mechura,
  Director
• Angus Smith,
  Director
• Donald P Deubel,
  SVP, Corporate Technologies
• Christopher Phelan,
  VP European Operations
• Walter Stanley Sobon,
  Executive VP and CFO
• David J Waksman,
  Senior Vice President
• Michael Dudley Mc Daniel,
  Director
• John P Neafsey,
  Director
• A Alexander Ii Taylor,
  Director
• Group L Pcolumn Group Gp, L...,
  
• Healthcare Capital Partners...,
  
• Adrian Senderowicz,
  Chief Medical Officer